Ipriflavone falls into the large group of isoflavonoids. Iprifavone as a bone building agent is a synthetic isoflavone derivative. It was first synthesized in Hungary by Doctor Laszlo Geuer while researching flavonoids as essential growth factors in animals. Soon after its synthesis ipriflavone was used in clinical testing. The substance was reportedly first used in veterinarian fodder and experimented with as an agent for enhancing endurance in animals. It was also investigated as a potential anti-anginal agent and was seen to influence the mitochrondrial energetic in a positive manner, with an oxygen sparing effect.
Numerous studies document a halting of bone loss and increases in bone density with the use of 600mg ipriflavone. Between 1989 and 2000,there were reported in the English language some 31 human clinical studies on ipriflavone. These studies involved a total of 4298 patients.Of these, 1495 patients were treated with ipriflavone. Of the 31 studies, 18 were placebo-controlled looking at bone mineral density. Of these 18, about one half showed ipriflavone to either enhance bone density or reduce bone loss significantly more than calcium alone. Although no early studies had fracture as their end point,three Italian studies strongly suggested that ipriflavone reduced vertebral fractures.
Humans have two isoforms of Prostaglandin H Synthase or cyclooxygenase: COX-1 and COX-2. COX-1 is cytoprotective. COX-2 inhibitors reduce inflammation without the risk of ulceration and kidney damage. The ideal nutraceutical would inhibit COX-2 synthesis while preserving COX-1 synthesis. The hypothesis for this research was that COX inhibitors would fall primarily into three categories: COX-2 specific inhibition, non-specific inhibition (COX-1 and COX-2), and minimal inhibition. The human Cayman COX inhibitor screening assay was used to determine the inhibitory concentration 50 (IC50) of COX-1/ COX-2 activity of each nutraceutical. Positive results were seen for ipriflavone, resveratrol, MSV-60, amentoflavone, ruscus extract and notoginseng. Glucosamine, nexrutine, and berberine did not inhibit either isoform.
Therefore, Ipriflavone is an isoflavone which has been studied for its potential in alleviating osteoporosis.
eBiochem.com can offer the above series of products
eBiochem.com was established in September 2010,focusing on e-commerce model innovation and business practice of bio- pharmaceutical and chemical industry, determining to build the world's leading one - stop on line trading platform of bio-pharmaceutical and chemical industry.
Please feel free to contact us, if you have any question.
Email: support-team@ebiochem.com
没有评论:
发表评论